CN102512360A - Torasemide pharmaceutical composition with stabilization and safety for injection - Google Patents
Torasemide pharmaceutical composition with stabilization and safety for injection Download PDFInfo
- Publication number
- CN102512360A CN102512360A CN2011104083584A CN201110408358A CN102512360A CN 102512360 A CN102512360 A CN 102512360A CN 2011104083584 A CN2011104083584 A CN 2011104083584A CN 201110408358 A CN201110408358 A CN 201110408358A CN 102512360 A CN102512360 A CN 102512360A
- Authority
- CN
- China
- Prior art keywords
- injection
- torasemide
- water
- adds
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a torasemide pharmaceutical composition with stabilization and safety for injection and its preparation method, especially relates to the torasemide pharmaceutical composition used for patients with requirement of rapid diuresis or congestive cardiac failure without oral diuresis, cirrhosis ascites, oedema caused by kidney diseases, the torasemide pharmaceutical composition is an injection preferably. The pharmaceutical composition is composed of active component torasemide, ethanol and polysorbate 80. The torasemide pharmaceutical composition for injection possesses stable pH value and low impurity content, and is capable of effectively raising the treatment effect of the products, minimizing the side reaction, raising the yield, reducing the cost and creating higher benefit.
Description
Technical field
The invention belongs to medical technical field, be specifically related to injection torasemide pharmaceutical composition of stability and safety and preparation method thereof.
Background technology
Hypertension is one of clinical frequently-occurring disease, how with multiple cardiovascular risk factors.China once carried out 3 large-scale Hypertensive Population sampling survey, the last promptly 2002, China more than 18 years old resident's hypertension prevalence be 18.8%, and obviously be rising trend, estimate that the existing hyperpietic of China surpasses 1.6 hundred million.
Diuretic is through natriuretic diuretic, reduces the content of sodium and water in the body-internal-circulation, makes blood volume decline and brings high blood pressure down.Can be divided into thiazide, medullary loop diuretic and isokalaemic diuretic according to its different effects characteristics.The hypotensive effect of diuretic is gentle, have no drug resistance and cheap, and Chang Zuowei basis medicine and other multiple antihypertensive drugs Combined application are used for that treatment is light, moderate hypertension, are specially adapted to the patients with hypertension of old people, merging heart failure.
Torasemide is nearly first loop diuretic of approval during the last ten years of FDA, 40 several national list marketings in the world at present.Because its powerful diuresis, less side effect is widely used in clinical.Along with hypertensive sickness rate raises year by year, the sales volume of torasemide also will increase year by year.China at present mainly with torasemide injection for wanting dosage form, SFDA approval torasemide injection is two families only, competitive pressure is less relatively.Good market prospect.
Common name: torasemide;
English name:
Torsemide;
Its structural formula is following:
Relative molecular mass: 348.43;
Molecular formula: C
16H
20N
4O
3S;
Chemical name: 1-isopropyl-3-［ (toluidino between 4--3-pyridine radicals) sulfonyl ］ urea;
Indication: be applicable to need rapid diuresis or can not oral diuretic congestive heart failure, the edema patient due to the cirrhotic ascites, kidney disease.
Mechanism of action: these article are sulfonylureas pyridines diuretic, and it acts on the Heng Lishi ascending thick limb of Henle's loop, suppress Na+/K+/2CL-carrier system; Make Na+ in the urine; The drainage of CL-and water increases, but to glomerular filtration rate, acid-base balance does not make significant difference in RPF or the body.
Usage and dosage: the edema due to the congestive heart failure, cirrhotic ascites: general predose is 5mg or 10mg, and once a day, slowly intravenous injection also can be diluted laggard row vein with 5% glucose solution or normal saline and injected; Can increase dosage to 20mg as curative effect is dissatisfied, once a day, every day, maximal dose was 40mg, was no more than a week course of treatment.
Torasemide has following characteristics:
(1) diuresis is strong: action intensity is 2 times of FRUSEMIDE at least.
(2) antihypertensive function is strong: hypotensive effect is stronger than hydrochlorothiazide, and is suitable with indopamide, and side effect is less than indopamide.
(3) acting duration is long: these article only need day clothes once.
(4) oral administration biaavailability is high, can reach 76～92%, is about 2 times of furosemide.Oral and parenterai administration curative effect are much at one.
(5) better tolerance, the toxicity incidence rate is low, a little less than the effect of row's potassium, the unlikely hypokalemia of life-time service, no liver, nephrotoxicity.
(6) clinical practice of these article is extensive, and market and consumption are big.
The invention of patent 200610039693.0 relates to field of pharmaceutical preparations, is specifically related to a kind of torasemide freeze-drying preparation and method for preparing.Increased the water solublity of torasemide effectively through adding sodium bicarbonate.Torasemide freeze-drying preparation of the present invention, steady quality, storage ability is good, and freeze-dried composition when dissolving again the solution clarity high, dissolving is fit to clinical use rapidly.
It is the method for preparing of injection and this injection of active ingredient with torasemide that the invention of patent 200710019868.6 provides a kind of.Torasemide injection stability of the present invention is compared prior art has had significantly raising.Said preparation contains solubilizing agent and stabilizing agent, and the pH value of solution is more than or equal to 9.0.Its preparation method is: measure a certain amount of water for injection, add account for the solubilizing agent of raw material gross weight 1%-50% after, press the preparation conventional amount used and add torasemide, treat that dissolving is complete after; Add the stabilizing agent that accounts for raw material gross weight 0.1-5%, moisturizing stirs to full dose, adds active carbon high-temp absorption 30 minutes; Decarburization is filtered, and adds medicinal basic, regulates pH value more than or equal to 9.0; Aseptic filtration, through intermediate fill after the assay was approved, sterilization, packing warehouse-in.The said preparation good stability, the dosing time is short, and production cost is low, and the injection that makes does not have hemolytic, blood vessel irritation and anaphylaxis, the related substance growth rate is also slower simultaneously.
Torasemide's pharmaceutical composition of conventional preparation injection, maximum deficiency, sterilising conditions is non-excessive sterilization, do not reach 121 ℃ 15 minutes, related substance is higher, and is of poor quality, in the storage storage condition required highly, needs cool dark place to preserve.
The injection torasemide pharmaceutical composition that the present invention obtains on the basis of a large amount of experiments, the advantage that has: safe, maximum contaminant is less than 5 ‰; Good stability is even room temperature is preserved reliable in quality.
Summary of the invention
In order to overcome the above-mentioned defective of prior art; A kind of stable torasemide's injection is provided, and the inventor has passed through further investigation, is surprisingly found out that; Select specific adjuvant (polyoxyethylene sorbitan monoleate), can obtain torasemide's injection of good stability, effective and safe.
Therefore, an object of the present invention is to provide that a kind of formulation and technology is simple, the injection torasemide pharmaceutical composition of good stability, effective and safe, this pharmaceutical composition contains torasemide, polyoxyethylene sorbitan monoleate.Torasemide of the present invention pharmaceutical composition; Be the pharmaceutical preparation that is fit to drug administration by injection; Be preferably injection, and when this injection is injection, it is formulated that it adds the injection water by torasemide, polyoxyethylene sorbitan monoleate, other pharmaceutic adjuvant (for example ethanol etc.).
Another object of the present invention provides a kind of industrialized mass of being convenient to, the simple torasemide of technology preparation of drug combination method.
Torasemide of the present invention pharmaceutical composition, wherein the prescription of compositions consists of: torasemide, ethanol, polyoxyethylene sorbitan monoleate and water for injection.
The 5-50g of torasemide
Ethanol 0.1-2.5L
Polyoxyethylene sorbitan monoleate 1-10g
Water for injection adds to 1L-5L
Process 1000
The prescription of injection is preferably: torasemide, ethanol, polyoxyethylene sorbitan monoleate and water for injection; And the weight ratio of each component is: torasemide: ethanol: polyoxyethylene sorbitan monoleate: water=5-50:100-2500:1-10:1000-5000, preferred aforementioned proportion is: 10-50:500-2500:1-5:1000-5000.
Preferred manufacturing procedure is:
In clean area, the polyoxyethylene sorbitan monoleate with recipe quantity adds in an amount of 70-90 ℃ water for injection earlier, stirring and dissolving, cooling; The ethanol that adds recipe quantity adds torasemide of recipe quantity again, is stirred to dissolving fully; Regulate pH value to 7.0-8.0, the active carbon of getting the 0.1%-0.5% (W/V) that accounts for the solution total amount adds an amount of water for injection and stirs, and adds water for injection to bright entirely; Agitation cycle is more than 15 minutes, and first coarse filtration is taken off charcoal, after microporous filter membrane (for example 0.22um filter membrane) fine straining; Behind the microporous filter membrane fine straining, can get fine straining liquid and carry out projects detections such as content, pH value, endotoxin, visible foreign matters, qualified back inflated with nitrogen, embedding; Pressure sterilizing is 15 minutes more than 121 ℃, and lamp inspection promptly gets.
Contain active component torasemide and adjuvant ethanol, polyoxyethylene sorbitan monoleate in the torasemide freeze-drying injectable powder of the present invention.
Torasemide of the present invention pharmaceutical composition dosage range is: 5-100mg/ props up, and is preferably 10-50mg/ and props up.
Active component torasemide in the prescription be prone to dissolve in water, so when processing injection, in research process, find; In neutral solution, torasemide is unstable, and being prone to related substance in the put procedure increases; The easy flavescence of solution colour has influenced the quality of medicine and the safety of clinical practice, finds through a large amount of experimental studies; Add polyoxyethylene sorbitan monoleate available buffer pH value Pharmaceutical is played Stabilization, solved not only that related substance exceeds standard the problem of solution changes color in the storage of injection; Also having solved simultaneously freeze-dried powder related substance in storage increases, and the quality that has guaranteed medicine is with stable.
The specific embodiment:
Below in conjunction with embodiment the present invention is done further explanation, make this area professional and technical personnel better understand the present invention.It is indicative that embodiment is merely, and means that never it limits scope of the present invention by any way.
Torasemide's injection of the present invention and prior art contrasts, and according to torasemide's injection pertinent literature and the disclosed prescription of package insert, prepares corresponding torasemide injection, as a comparison example.
Embodiment 1
The 50g of torasemide
Ethanol 2.5L
Polyoxyethylene sorbitan monoleate 10g
Water for injection 5L
Process 1000
Method for preparing is:
In clean area, the polyoxyethylene sorbitan monoleate with recipe quantity adds in an amount of 70-90 ℃ water for injection earlier, stirring and dissolving, cooling; The ethanol that adds recipe quantity adds torasemide of recipe quantity again, is stirred to dissolving fully; Regulate pH value to 7.0-8.0, the active carbon of getting the 0.1%-0.5% (W/V) that accounts for the solution total amount adds an amount of water for injection and stirs, and adds water for injection to bright entirely; Agitation cycle is more than 15 minutes, and first coarse filtration is taken off charcoal, after microporous filter membrane (for example 0.22um filter membrane) fine straining; Behind the microporous filter membrane fine straining, can get fine straining liquid and carry out projects detections such as content, pH value, endotoxin, visible foreign matters, qualified back inflated with nitrogen, embedding; Pressure sterilizing is 15 minutes more than 121 ℃, and lamp inspection promptly gets.
Embodiment 2
The 20g of torasemide
Ethanol 1L
Polyoxyethylene sorbitan monoleate 4g
Water for injection 2L
Process 1000
Method for preparing is:
In clean area, the polyoxyethylene sorbitan monoleate with recipe quantity adds in an amount of 70-90 ℃ water for injection earlier, stirring and dissolving, cooling; The ethanol that adds recipe quantity adds torasemide of recipe quantity again, is stirred to dissolving fully; Regulate pH value to 7.0-8.0, the active carbon of getting the 0.1%-0.5% (W/V) that accounts for the solution total amount adds an amount of water for injection and stirs, and adds water for injection to bright entirely; Agitation cycle is more than 15 minutes, and first coarse filtration is taken off charcoal, after microporous filter membrane (for example 0.22um filter membrane) fine straining; Behind the microporous filter membrane fine straining, can get fine straining liquid and carry out projects detections such as content, pH value, endotoxin, visible foreign matters, qualified back inflated with nitrogen, embedding; Pressure sterilizing is 15 minutes more than 121 ℃, and lamp inspection promptly gets.
Embodiment 3
The 10g of torasemide
Ethanol 0.5L
Polyoxyethylene sorbitan monoleate 2g
Water for injection 1L
Process 1000
Method for preparing is:
In clean area, the polyoxyethylene sorbitan monoleate with recipe quantity adds in an amount of 70-90 ℃ water for injection earlier, stirring and dissolving, cooling; The ethanol that adds recipe quantity adds torasemide of recipe quantity again, is stirred to dissolving fully; Regulate pH value to 7.0-8.0, the active carbon of getting the 0.1%-0.5% (W/V) that accounts for the solution total amount adds an amount of water for injection and stirs, and adds water for injection to bright entirely; Agitation cycle is more than 15 minutes, and first coarse filtration is taken off charcoal, after microporous filter membrane (for example 0.22um filter membrane) fine straining; Behind the microporous filter membrane fine straining, can get fine straining liquid and carry out projects detections such as content, pH value, endotoxin, visible foreign matters, qualified back inflated with nitrogen, embedding; Pressure sterilizing is 15 minutes more than 121 ℃, and lamp inspection promptly gets.
Embodiment 4
The 10g of torasemide
Ethanol 0.5L
Polyoxyethylene sorbitan monoleate 2g
Water for injection 2L
Process 1000
Method for preparing is:
In clean area, the polyoxyethylene sorbitan monoleate with recipe quantity adds in an amount of 70-90 ℃ water for injection earlier, stirring and dissolving, cooling; The ethanol that adds recipe quantity adds torasemide of recipe quantity again, is stirred to dissolving fully; Regulate pH value to 7.0-8.0, the active carbon of getting the 0.1%-0.5% (W/V) that accounts for the solution total amount adds an amount of water for injection and stirs, and adds water for injection to bright entirely; Agitation cycle is more than 15 minutes, and first coarse filtration is taken off charcoal, after microporous filter membrane (for example 0.22um filter membrane) fine straining; Behind the microporous filter membrane fine straining, can get fine straining liquid and carry out projects detections such as content, pH value, endotoxin, visible foreign matters, qualified back inflated with nitrogen, embedding; Pressure sterilizing is 15 minutes more than 121 ℃, and lamp inspection promptly gets.
The comparative example 1
200710019868.6 write out a prescription 1
Prescription 1
The 20g of torasemide
Trometamol 2g
Sodium hydroxide 2g
Polyethylene Glycol 100g
Water for injection adds to 1000ml
Preparation technology: measure a certain amount of water for injection, add torasemide after the adding solubilizing agent, wait to dissolve complete back and add stabilizing agent, moisturizing is to bright entirely; Stir, add active carbon high-temp absorption 30 minutes, decarbonization filtering; Adding is used as medicine has alkali (sodium hydroxide, sodium-acetate buffer), regulates pH to 9.5 aseptic filtration; Through intermediate fill after the assay was approved, sterilization, packing warehouse-in.
Test Example 1
The torasemide injection key index of the embodiment of the invention and comparative example's preparation: character, pH value, visible foreign matters, clarity, related substance and content etc. are tested, and the result sees table 1.
Result of the test shows that torasemide of the present invention pharmaceutical composition quality is superior to the comparative example.
Test Example 2
Make an experiment according to 2010 editions two appendix XIXC stability tests of Chinese Pharmacopoeia guideline; Key index to embodiment and Comparative Examples: character, acidity (pH), visible foreign matters, clarity, related substance and content are tested, and testing result is seen table 2,3.
(illumination 4500 ± 500LX) result of the tests are seen table 2 to influence factor's high temperature (60 ℃ ± 2 ℃ of temperature) in illumination.
Sample thief; Put into row by real packet receiving and quicken (temperature is that 40 ℃ ± 2 ℃, relative humidity are under 75% ± 5% the condition) 6 months and long-term (temperature is that 25 ℃ ± 2 ℃, relative humidity are under 60% ± 10% the condition) experimental study in 24 months; Detect according to table 3 point in time sampling, the result is following.
Product each item key index in influence factor, acceleration, long term test of the present invention's preparation does not have significant change, and especially clarity and visible foreign matters item are superior to Comparative Examples, quality assurance, good stability.
Test Example 3
The specific safety property test of torasemide's injection that method for preparing of the present invention obtains
The hemolytic test
Torasemide injection 0.1mg/ml of the present invention does not have obvious haemolysis, meets the requirement of intravenous injection medication security inspection.Show that concentration is that the torasemide injection of 0.1mg/ml is not seen haemolysis and agglutination, its blood vessel irritation of intravenous injection medication as a result test meets security requirement.
The injection torasemide pharmaceutical composition pH value that the present invention obtains is stable, and impurity content is low, has improved the therapeutic effect of product effectively, has reduced side reaction; Improve yield simultaneously, reduced cost, created higher benefit.
Claims (2)
1.
A kind of torasemide's pharmaceutical composition of injection; It is characterized in that this injection is an injection; Wherein each components by weight is in the injection: torasemide, ethanol, polyoxyethylene sorbitan monoleate and water for injection; And the weight ratio of each component is: torasemide: ethanol: polyoxyethylene sorbitan monoleate: water=5-50:100-2500:1-10:1000-5000, and preferred aforementioned proportion is: 10-50:500-2500:1-5:1000-5000, the pH value scope gets final product in the 7.0-8.0 scope; Prepare 1000, form as follows:
The 5-50g of torasemide
Ethanol 0.1-2.5L
Polyoxyethylene sorbitan monoleate 1-10g
Water for injection adds to 1L-5L.
2.
The method for preparing of torasemide according to claim 1 injection, wherein the method for preparing of injection comprises the following steps:
In clean area, the polyoxyethylene sorbitan monoleate with recipe quantity adds in an amount of 70-90 ℃ water for injection earlier, stirring and dissolving, cooling; The ethanol that adds recipe quantity adds torasemide of recipe quantity again, is stirred to dissolving fully; Regulate pH value to 7.0-8.0, the active carbon of getting the 0.1%-0.5% (W/V) that accounts for the solution total amount adds an amount of water for injection and stirs, and adds water for injection to bright entirely; Agitation cycle is more than 15 minutes, and first coarse filtration is taken off charcoal, after microporous filter membrane (for example 0.22um filter membrane) fine straining; Behind the microporous filter membrane fine straining, can get fine straining liquid and carry out projects detections such as content, pH value, endotoxin, visible foreign matters, qualified back inflated with nitrogen, embedding; Pressure sterilizing is 15 minutes more than 121 ℃, and lamp inspection promptly gets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110408358.4A CN102512360B (en) | 2011-12-09 | 2011-12-09 | Torasemide pharmaceutical composition with stabilization and safety for injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110408358.4A CN102512360B (en) | 2011-12-09 | 2011-12-09 | Torasemide pharmaceutical composition with stabilization and safety for injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102512360A true CN102512360A (en) | 2012-06-27 |
| CN102512360B CN102512360B (en) | 2014-06-25 |
Family
ID=46283623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110408358.4A Active CN102512360B (en) | 2011-12-09 | 2011-12-09 | Torasemide pharmaceutical composition with stabilization and safety for injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102512360B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109200022A (en) * | 2017-06-29 | 2019-01-15 | 南京优科生物医药研究有限公司 | A kind of injection Torasemide and its preparation process |
| CN111741745A (en) * | 2018-02-16 | 2020-10-02 | 威隆股份公司 | Multipurpose torasemide composition |
| CN112168776A (en) * | 2020-10-30 | 2021-01-05 | 康普药业股份有限公司 | Low-impurity high-stability torasemide injection and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833642A (en) * | 2006-04-20 | 2006-09-20 | 南京海辰药业有限公司 | Torasemide freeze-drying preparation and prepn. method |
| CN1872032A (en) * | 2006-06-30 | 2006-12-06 | 宛六一 | Torasemide soft capsule, and preparation method |
| CN101007003A (en) * | 2007-02-01 | 2007-08-01 | 扬子江药业集团南京海陵药业有限公司 | A stable torasemide injection and its preparation method |
-
2011
- 2011-12-09 CN CN201110408358.4A patent/CN102512360B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1833642A (en) * | 2006-04-20 | 2006-09-20 | 南京海辰药业有限公司 | Torasemide freeze-drying preparation and prepn. method |
| CN1872032A (en) * | 2006-06-30 | 2006-12-06 | 宛六一 | Torasemide soft capsule, and preparation method |
| CN101007003A (en) * | 2007-02-01 | 2007-08-01 | 扬子江药业集团南京海陵药业有限公司 | A stable torasemide injection and its preparation method |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109200022A (en) * | 2017-06-29 | 2019-01-15 | 南京优科生物医药研究有限公司 | A kind of injection Torasemide and its preparation process |
| CN111741745A (en) * | 2018-02-16 | 2020-10-02 | 威隆股份公司 | Multipurpose torasemide composition |
| CN111741745B (en) * | 2018-02-16 | 2024-03-26 | 威隆股份公司 | Multipurpose torsemide composition |
| CN112168776A (en) * | 2020-10-30 | 2021-01-05 | 康普药业股份有限公司 | Low-impurity high-stability torasemide injection and preparation method thereof |
| CN112168776B (en) * | 2020-10-30 | 2022-05-03 | 康普药业股份有限公司 | Low-impurity high-stability torasemide injection and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102512360B (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103961364A (en) | Medicine composition containing multiple vitamins as well as preparation method and detection method of medicine composition | |
| CN101537012B (en) | Complex vitamin freeze-dried powder injection and preparation method thereof | |
| CN106659711A (en) | Durable preparation of an injectable of melatonin exhibiting long-term stability | |
| CN101357118A (en) | Medicine composition containing 15 kinds of amino acid and preparation method thereof | |
| WO2019006741A1 (en) | Preparation of pulsatilla saponin b4 for injection | |
| CN101716149A (en) | New precursor medicinal preparation | |
| CN102512360B (en) | Torasemide pharmaceutical composition with stabilization and safety for injection | |
| CN101007003A (en) | A stable torasemide injection and its preparation method | |
| CN103006554B (en) | Ornidazole injection and preparation method thereof | |
| CN100435803C (en) | Use of taurine in preparation of injection containing puerarin | |
| US20040242534A1 (en) | Lyophilized powder of lentinan and the process of preparation thereof | |
| CN106943346B (en) | Methdigoxin liquid preparation, preparation method and application thereof | |
| CN104706655B (en) | Meglumine cyclic adenosine for injecta powder-injection pharmaceutical composition and preparation method | |
| CN103239442A (en) | Preparation method of compound amino acid injection (18AA-V) | |
| CN106959347A (en) | Meglumine cyclic adenosine injection pharmaceutical composition and its quality control method and preparation method | |
| CN101417105B (en) | Zedoary turmeric oil glucose injection and preparation method thereof | |
| CN103055305A (en) | A lyophilized preparation of a cytochrome C-containing pharmaceutical composition for injection and a preparation method thereof | |
| CN115518037A (en) | Safe and stable-quality levosimendan injection composition and preparation method thereof | |
| CN101513400A (en) | Ampelopsin and basic amino acid solubilizing system | |
| CN107019675A (en) | Adenosine cyclophosphate for injection freeze drying powder injection pharmaceutical composition and quality control method and preparation method | |
| CN104000877A (en) | Blood glucose reducing composition and application thereof | |
| CN106860446A (en) | Pediatric compound amino acid injection 19AA I compositions and the method for reducing its oxygen content | |
| CN101703466A (en) | Borneol injection and preparation method thereof | |
| CN101129374B (en) | Vinflunine pharmaceutical composition and method of producing the same and application of the same | |
| CN100546585C (en) | Compound puerarin injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |